title: Systemic treatment of endometrial cancer: what is doxorubicin's role?
authors.affiliation: Montefiore/Albert Einstein School of Medicine, Bronx, NY.
authors.forename: Mendel
authors.initials: M
authors.lastname: Goldfinger
authors.affiliation: Galdakao-Usánsolo Hospital, Galdakao, Spain.
authors.forename: Isabela
authors.initials: I
authors.lastname: Diaz
authors.affiliation: New York University Cancer Institute, New York, NY franco.muggia@nyumc.org.
authors.forename: Franco
authors.initials: F
authors.lastname: Muggia
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin